Importantly, we observed that in multiple subgroups, including T stage (T1, T3), pathologic stage (I, III), histologic grade (G1, G2, G3, and G4), AFP ≤400, and adjacent hepatic tissue inflammation (none, mild, and severe), HCC patients with higher RPL32 expression exhibited lower survival probabilities (Figure S4A–I). The gene discussed is RPL32; the disease is hepatocellular carcinoma.